Umeclidinium

Category: pharmacological

Aliases: Incruse Ellipta

Pharmacological Mechanism

Inhaled LAMA — once-daily M3-preferring muscarinic antagonist for COPD. Component of triple-therapy inhalers (Trelegy = umeclidinium + vilanterol + fluticasone furoate). Quaternary structure limits systemic absorption.

Half-Life (t½)

INH: 11h

Dosing Guidelines

• INH: Typical 0.0625 mg (Range: 0.0625–0.0625 mg)

Target Organ Systems

• nervous
• respiratory

Pathways It Modulates

• Acetylcholine synthesis + degradation (inhibitor) — muscarinic M3
• Asthma (inhibitor) — M3 (LAMA component of Trelegy ICS/LABA/LAMA)
• Muscarinic ACh receptor subtypes (inhibitor) — M3 LAMA (Trelegy component)

Chemical Identifiers

• PubChem CID: 11519070
• Formula: C29H34NO2+
• Molecular weight: 508.55 g/mol
• InChIKey: FVTWTVQXNAJTQP-UHFFFAOYSA-N
• SMILES: C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5